Serum complement C3 correlates with insulin resistance in never treated psoriatic arthritis patients

Clinical Rheumatology

Volumn 33, Issue 12, 2014, Pages 1759-1764

  Ursini, Francesco ^a   Grembiale, Alessandro ^a   Naty, Saverio ^a   Grembiale, Rosa Daniela ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Arthritis; Complement C3; Insulin resistance; Psoriatic

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTIRHEUMATIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BODY MASS; CAPILLARY PHOTOMETRY; CHOLESTEROL BLOOD LEVEL; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; IMMUNOASSAY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PHOTOMETRY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; TURBIDIMETRY; ANALYSIS; BLOOD; COMPLICATION; INFLAMMATION; METABOLISM; MIDDLE AGED; REGRESSION ANALYSIS;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BLOOD GLUCOSE; BLOOD SEDIMENTATION; BODY MASS INDEX; C-REACTIVE PROTEIN; COMPLEMENT C3; CROSS-SECTIONAL STUDIES; FEMALE; HOMEOSTASIS; HUMANS; IMMUNOASSAY; INFLAMMATION; INSULIN RESISTANCE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; REGRESSION ANALYSIS;

EID: 84925454719     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2366-4     Document Type: Article

References (43)

1. Ritchlin CT et al (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68(9):1387–1394
2. Boehncke WH, Boehncke S (2012) Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep 14(4):343–348
3. Arumugam R, McHugh NJ (2012) Mortality and causes of death in psoriatic arthritis. J Rheumatol Suppl 89:32–35
4. Jon Love T et al (2012) Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 71(8):1273–1277
5. Ghiasi M et al (2011) Psoriasis and increased prevalence of hypertension and diabetes mellitus. Indian J Dermatol 56(5):533–536
6. Holzer M et al (2012) Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res 53(8):1618–1624
7. Tam LS et al (2008) Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 59(9):1322–1331
8. Azfar RS et al (2012) Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis diabetes mellitus and psoriasis. Arch Dermatol 148(9):995–1000
9. Tam LS et al (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology (Oxford) 47(5):718–723
10. Jamnitski A et al (2012) Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 72(2):211–216
11. Reaven GM (1988) Banting lecture, 1998. Role of insulin resistance in human disease. Diabetes 37(12):1595–1607
12. Reilly MP, Rader DJ (2003) The metabolic syndrome: more than the sum of its parts? Circulation 108(13):1546–1551
13. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237(3):E214–E223
14. Matthews DR et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419
15. Gisondi P et al (2007) Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case–control study. Br J Dermatol 157(1):68–73
16. Love TJ et al (2011) Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003–2006. Arch Dermatol 147(4):419–424
17. Balci A et al (2010) Increased amount of visceral fat in patients with psoriasis contributes to metabolic syndrome. Dermatology 220(1):32–37
18. Ucak S et al (2006) Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis. J Eur Acad Dermatol Venereol 20(5):517–522
19. Martinez-Abundis E et al (2007) Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res 299(9):461–465
20. Taylor W et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673
21. van der Heijde DM et al (1992) Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51(2):177–181
22. Garrett S et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291
23. Calin A et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285
24. Stern SE et al (2005) Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 54(2):333–339
25. Eder L et al (2012) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis (In Press).
26. Han C et al (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33(11):2167–2172
27. Hertle E, van Greevenbroek MM, Stehouwer CD (2012) Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia 55(4):881–884
28. Yang S et al (2011) Serum complement C3 has a stronger association with insulin resistance than high-sensitivity C-reactive protein in women with polycystic ovary syndrome. Fertil Steril 95(5):1749–1753
29. Wang B et al (2011) Serum complement C3 has a stronger association with insulin resistance than high sensitive C-reactive protein in non-diabetic Chinese. Inflamm Res 60(1):63–68
30. Muscari A et al (2007) Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: comparison study in an elderly population. Diabetes Care 30(9):2362–2368
31. Baldo A et al (1993) The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J Clin Invest 92(3):1543–1547
32. Maslowska M et al (1999) Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur J Clin Invest 29(8):679–686
33. Faraj M et al (2003) Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 88(4):1594–1602
34. Kalant D et al (2005) C5L2 is a functional receptor for acylation-stimulating protein. J Biol Chem 280(25):23936–23944
35. Cianflone K et al (1994) Adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis. Biochemistry 33(32):9489–9495
36. Van Harmelen V et al (1999) Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem 274(26):18243–18251
37. Germinario R et al (1993) Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. Metabolism 42(5):574–580
38. Volanakis JE (1995) Transcriptional regulation of complement genes. Annu Rev Immunol 13:277–305
39. Peake PW et al (1997) Detection and quantification of the control proteins of the alternative pathway of complement in 3T3-L1 adipocytes. Eur J Clin Invest 27(11):922–927
40. Gabrielsson BG et al (2003) High expression of complement components in omental adipose tissue in obese men. Obes Res 11(6):699–708
41. Peters MJ et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331
42. Mok CC et al (2011) Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 63(2):195–202
43. Chimenti MS et al (2012) Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol 30(1):23–30